[S,S]-Reboxetine Dose-Range Finding Trial

Pfizer

Status and phase

Completed

Phase 2

Conditions

Pain

Treatments

Drug: [S,S]-Reboxetine

Study type

Interventional

Funder types

Industry

Identifiers

NCT00288652

A6061026

Details and patient eligibility

About

The purpose of this study is to determine the effectiveness of different doses of [S,S]-Reboxetine in the treatment of chronic pain following a shingles infection

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients must have pain present for more than 3 months after the healing of shingles skin rash
Patients at screening must have a score >/=40 mm on the pain visual analogue scale

Exclusion criteria

Patients with significant renal and hepatic impairment
Patients with other severe pain, that may impair the self-assessment of the pain due to shingles
Patients with clinically abnormal electrocardiogram